Therapeutic Advances in Medical Oncology
@tamedoncol.bsky.social
A SAGE Publishing Gold #openaccess journal | Publishing innovative clinically focused articles on the medical treatment of cancer| PubMed Indexed | IF: 4.2
ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch
🔗 Read the article: buff.ly/kbZ7ewQ
🔗 Read the article: buff.ly/kbZ7ewQ
December 10, 2025 at 8:15 AM
ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch
🔗 Read the article: buff.ly/kbZ7ewQ
🔗 Read the article: buff.ly/kbZ7ewQ
Immunotherapy is reshaping treatment for ES-SCLC. ICIs like atezolizumab & durvalumab push survival beyond 1 year. New targets & novel immune drugs may bring fresh hope.
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
December 8, 2025 at 8:15 AM
Immunotherapy is reshaping treatment for ES-SCLC. ICIs like atezolizumab & durvalumab push survival beyond 1 year. New targets & novel immune drugs may bring fresh hope.
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
EVs-exRNA in bladder cancer: progress, challenges & future prospects for clinical application. Read more buff.ly/WX2dUSP
#Oncology #PrecisionMedicine
#Oncology #PrecisionMedicine
December 5, 2025 at 8:15 AM
EVs-exRNA in bladder cancer: progress, challenges & future prospects for clinical application. Read more buff.ly/WX2dUSP
#Oncology #PrecisionMedicine
#Oncology #PrecisionMedicine
EBV-positive gastric cancer is not one disease - it’s six. New review maps six EBVaGC subtypes and links each to targeted therapies, from immune checkpoint inhibitors to lytic‑induction and PI3K/Akt strategies. Read the full review buff.ly/e6lgBX9 #Oncology #GastricCancer
December 4, 2025 at 8:35 AM
EBV-positive gastric cancer is not one disease - it’s six. New review maps six EBVaGC subtypes and links each to targeted therapies, from immune checkpoint inhibitors to lytic‑induction and PI3K/Akt strategies. Read the full review buff.ly/e6lgBX9 #Oncology #GastricCancer
Genetic profiling matters: MUTYH mutation-associated PanNET shows aggressive course, frequent grade progression, and poor OS. Multinational data highlight need for tailored strategies. #Oncology #PrecisionMedicine
buff.ly/5Jh8NHy
buff.ly/5Jh8NHy
December 3, 2025 at 8:15 AM
Genetic profiling matters: MUTYH mutation-associated PanNET shows aggressive course, frequent grade progression, and poor OS. Multinational data highlight need for tailored strategies. #Oncology #PrecisionMedicine
buff.ly/5Jh8NHy
buff.ly/5Jh8NHy
Delayed addition of PD-1/PD-L1 inhibitors to chemo may improve survival in ES-SCLC patients vs early start. Median OS: 24 vs 18.8 months after PSM. #Oncology #SCLC #Immunotherapy
buff.ly/TcJIvr4
buff.ly/TcJIvr4
December 1, 2025 at 8:15 AM
Delayed addition of PD-1/PD-L1 inhibitors to chemo may improve survival in ES-SCLC patients vs early start. Median OS: 24 vs 18.8 months after PSM. #Oncology #SCLC #Immunotherapy
buff.ly/TcJIvr4
buff.ly/TcJIvr4
Fresh evidence on IASLC residual tumor classification: Run linked to poorer survival in operable NSCLC. Full systematic review/meta-analysis: buff.ly/EoWjoVI #NSCLC #IASLC
November 28, 2025 at 12:15 PM
Fresh evidence on IASLC residual tumor classification: Run linked to poorer survival in operable NSCLC. Full systematic review/meta-analysis: buff.ly/EoWjoVI #NSCLC #IASLC
Adding immune checkpoint inhibitors to neoadjuvant chemo improves pCR in advanced gastric cancer. Real-world evidence from a retrospective cohort study. Read more: buff.ly/xzkJ8cL #GastricCancer #Oncology
November 25, 2025 at 8:15 AM
Adding immune checkpoint inhibitors to neoadjuvant chemo improves pCR in advanced gastric cancer. Real-world evidence from a retrospective cohort study. Read more: buff.ly/xzkJ8cL #GastricCancer #Oncology
Network meta-analysis of 11 RCTs: EV+pembrolizumab ranks highest for OS, PFS & ORR in la/mUC. Safety acceptable vs chemo. Details buff.ly/Wsqr2nQ
#CancerResearch #BladderCancer
#CancerResearch #BladderCancer
November 23, 2025 at 8:15 AM
Network meta-analysis of 11 RCTs: EV+pembrolizumab ranks highest for OS, PFS & ORR in la/mUC. Safety acceptable vs chemo. Details buff.ly/Wsqr2nQ
#CancerResearch #BladderCancer
#CancerResearch #BladderCancer
Many breast cancer survivors face diminished quality of life due to estrogen deprivation.
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
November 20, 2025 at 8:15 AM
Many breast cancer survivors face diminished quality of life due to estrogen deprivation.
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
November 17, 2025 at 8:15 AM
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
November 13, 2025 at 8:15 AM
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
November 10, 2025 at 9:21 AM
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
November 1, 2025 at 7:15 AM
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:59 PM
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:57 PM
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
October 10, 2025 at 3:54 PM
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:51 PM
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:48 PM
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:53 PM
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:52 PM
Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:50 PM
Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:48 PM
Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:47 PM
Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 26, 2025 at 2:47 PM
Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....